Proactive - Interviews for investors
20/20 BioLabs blood test platform targeting early detection of hard-to-screen Cancers
20/20 BioLabs CEO Jonathan Cohen discusses the company's blood-based diagnostic platform for early cancer detection. The platform targets hard-to-detect cancers and offers a longevity test measuring biomarkers associated with chronic inflammation.